Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.64 |
| ▸ | MET | P08581 | 5/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.62 |
| ▸ | FLT3 | P36888 | 2/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.58 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038459 | 0.79 | ALK (0.63) | ALKMETPTK2FLT3MAP3K7 | |
| SCHEMBL1038670 | 0.77 | AXL (0.63) | EGFRALKMETFLT3JAK3 | |
| SCHEMBL28434966 | 0.77 | ALK (0.98) | EGFRALKMETFLT3 | |
| SCHEMBL1035784 | 0.77 | ALK (0.61) | EGFRALKFLT3 | |
| SCHEMBL1038446 | 0.77 | ALK (0.63) | EGFRALKMETFLT3JAK3 | |
| SCHEMBL12726513 | 0.77 | MAPK9 (0.67) | EGFRALKMETPTK2GLO1 | |
| SCHEMBL28438911 | 0.77 | ALK (1.00) | EGFRALKMETFLT3 | |
| SCHEMBL1038713 | 0.77 | ALK (0.62) | EGFRALKFLT3 | |
| SCHEMBL12765458 | 0.77 | ALK (0.62) | EGFRALKFLT3 | |
| SCHEMBL1038017 | 0.76 | EGFR (0.66) | EGFRALKMETFLT3MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | EGFR 2061/4885ALK 846/4885MET 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.